PathoLase's first laser solution now available in the marketplace addresses the pathogens that cause toenail fungus (Onychomycosis), an infection that afflicts an estimated 40 million people in the US alone. With Series A private equity capital recently secured from Nexus Medical Partners, PathoLase is rapidly placing its patented technology in the hands of leading podiatrists around the country. Dr Cozzarelli and Associates are the first office on the East Coast to provide this modality. PathoLase is the only medical laser technology currently available in the marketplace that kills the pathogens that cause toenail fungus. It presently kills T. Menta, T. Rubrum, Yeast Mold and Pseudomonas bacteria. The company expects to introduce its leading edge laser technology into another 20 major markets in the next several months. Led by medical laser pioneer, David Harris, PhD, Director of Science & Regulatory Affairs for PathoLase, the company recently brought its patented laser technology to market after several years of research and development. With over 20 years of medical laser development to his credit, Dr. Harris has overseen the development of this groundbreaking technology. "With an estimated 40 million people in the US suffering from toenail fungus infections, PathoLase is committed to making our PinPointe FootLaser system available to as many sufferers as quickly as we can throughout the US," noted John Strisower, CEO of PathoLase. This treatment is presently being advertised on NJ101.5, FM. 1-888-NAIL-LZR. Please click here to READ our PinPointe FootLaser brochure which contains answers to frequently asked questions.
Please click below to SEE our VIDEO about PinPointe FootLaser which contains answers to frequently asked questions.
Please click here to SEE and HEAR our RADIO Ad on NJ101.5, FM about PinPointe FootLaser which contains answers to frequently asked questions.